You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

stage I adult diffuse mixed cell lymphoma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Adult Patients Who Initiate Systemic Treatment for

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional
  • Graz, Austria
  • +8 more
Sep 19, 2022

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma Trial in United States

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Mogamulizumab
  • Pembrolizumab
  • Sacramento, California
  • +7 more
Sep 15, 2022

DLBCL, Chronic Lymphocytic Leukemia, Follicular Lymphoma Trial in New Haven, Worcester, Dallas (ABBV-319)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
Aug 22, 2022

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma Trial in United States (Abexinostat, Ibrutinib)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Mantle Cell Lymphoma
  • Basking Ridge, New Jersey
  • +6 more
Aug 11, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

DLBCL (DLBCL) Trial (Tisagenlecleucel)

Withdrawn
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • (no location specified)
Feb 25, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

Recruiting
  • Waldenstrom Macroglobulinemia
  • +8 more
  • Iopofosine I 131 single dose
  • +2 more
  • Redlands, California
  • +42 more
Dec 30, 2022

CD20 Positive, Recurrent DLBCL, Refractory DLBCL Trial in Buffalo (drug, other, biological)

Active, not recruiting
Has Results
  • CD20 Positive
  • +6 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 11, 2021

Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,

Recruiting
  • Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
  • +13 more
  • Scottsdale, Arizona
  • +2 more
Jun 1, 2022

Refractory Diffuse Large B-cell Lymphoma, Refractory DLBCL, Not Otherwise Specified, Recurrent DLBCL Trial in Duarte, Saint

Recruiting
  • Refractory Diffuse Large B-cell Lymphoma
  • +4 more
  • Duarte, California
  • +2 more
Aug 9, 2022

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

Lymphoma, Large B-Cell, Diffuse Trial in Saint Louis, Columbus (Brentuximab vedotin, Lenalidomide)

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Saint Louis, Missouri
  • +1 more
Feb 16, 2022

Lymphoma Trial in Scottsdale, Jacksonville, Rochester (biological, drug, genetic, other)

Active, not recruiting
  • Lymphoma
  • pegfilgrastim
  • +8 more
  • Scottsdale, Arizona
  • +2 more
Jan 7, 2022

Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
Nov 17, 2022

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Münster (L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • L19-IL2 - Ph I
  • +2 more
  • Münster, Germany
    Münster University Hospital
Apr 19, 2022

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in United Kingdom, United States (AUTO3)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • AUTO3
  • Duarte, California
  • +10 more
Oct 19, 2022

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in New York (Venetoclax, Tazemetostat)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • New York, New York
    Weill Cornell Medicine/NewYork-Presberteryian Hospital
Jan 18, 2023

Lymphoma Trial in China (Obinutuzumab, Glofitamab, Tocilizumab)

Recruiting
  • Lymphoma
  • Beijing, China
  • +6 more
Aug 4, 2022

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, DLBCL Trial in United States (KT-413)

Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Washington, District of Columbia
  • +5 more
Nov 29, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell

Recruiting
  • Recurrent Adult T-Cell Leukemia/Lymphoma
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 18, 2022